Jumpcode Genomics
John Estill has a wealth of experience in the finance and operations sector. John began their career in 2004 as an Executive Consultant at JLJ Ventures. In 2006, they became the CFO of BlueSky Medical Group, Inc. and in 2008, they were promoted to CEO of Hygeia II Medical Group, Inc. In 2010, they were appointed CFO & VP San Diego Operations at BeneChill, where they were responsible for worldwide financial operations and all San Diego operations. In 2016, they took on the role of COO at 3D Learning Group, and in 2017 they became a Consulting CFO at Signature Analytics. In 2019, they joined Optima Office as a Consulting CFO, and in 2021 they became the Director of Finance and Operations at Jumpcode Genomics.
John Estill received a Bachelor of Science in Business Administration from California State University, Fresno.
This person is not in any teams
Jumpcode Genomics
Jumpcode Genomic's patented technology unlocks the power of Next Generation Sequencing by improving sensitivity, reducing costs, simplifying workflows, and removing bias. Researchers around the world are using our CRISPRClean technology in the fields of infectious disease, oncology, consumer genomics, food science, and basic research.